These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21485816)

  • 21. The hierarchy of environmental health and safety practices in the U.S. nanotechnology workplace.
    Engeman CD; Baumgartner L; Carr BM; Fish AM; Meyerhofer JD; Satterfield TA; Holden PA; Harthorn BH
    J Occup Environ Hyg; 2013; 10(9):487-95. PubMed ID: 23927041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using expert elicitation to prioritize resource allocation for risk identification for nanosilver.
    Fauss E; Gorman ME; Swami N
    J Law Med Ethics; 2009; 37(4):770-80. PubMed ID: 20122116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects, challenges and need for regulation of nanotechnology with special reference to India.
    Mishra M; Dashora K; Srivastava A; Fasake VD; Nag RH
    Ecotoxicol Environ Saf; 2019 Apr; 171():677-682. PubMed ID: 30658303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Demand for command: responding to technological risks and scientific uncertainties.
    Stokes E
    Med Law Rev; 2013; 21(1):11-38. PubMed ID: 23329016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanomaterials: a challenge for toxicological risk assessment?
    Haase A; Tentschert J; Luch A
    Exp Suppl; 2012; 101():219-50. PubMed ID: 22945571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A global view of regulations affecting nanomaterials.
    Hansen SF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(5):441-9. PubMed ID: 20533518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Science and regulation. FDA's approach to regulation of products of nanotechnology.
    Hamburg MA
    Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
    [No Abstract]   [Full Text] [Related]  

  • 28. [Risks associated with nanotechnology based on European Union legislation].
    Hydzik P
    Przegl Lek; 2012; 69(8):490-1. PubMed ID: 23243915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidance for safe handling of nanomaterials.
    Dhawan A; Shanker R; Das M; Gupta KC
    J Biomed Nanotechnol; 2011 Feb; 7(1):218-24. PubMed ID: 21485878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The US must help set international standards for nanotechnology.
    Murashov V; Howard J
    Nat Nanotechnol; 2008 Nov; 3(11):635-6. PubMed ID: 18989319
    [No Abstract]   [Full Text] [Related]  

  • 31. The status of in vitro toxicity studies in the risk assessment of nanomaterials.
    Park MV; Lankveld DP; van Loveren H; de Jong WH
    Nanomedicine (Lond); 2009 Aug; 4(6):669-85. PubMed ID: 19663595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations on the EU definition of a nanomaterial: science to support policy making.
    Bleeker EA; de Jong WH; Geertsma RE; Groenewold M; Heugens EH; Koers-Jacquemijns M; van de Meent D; Popma JR; Rietveld AG; Wijnhoven SW; Cassee FR; Oomen AG
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):119-25. PubMed ID: 23200793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanomaterial health effects--part 1: background and current knowledge.
    Powell MC; Kanarek MS
    WMJ; 2006 Mar; 105(2):16-20. PubMed ID: 16628969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dealing with nanosafety around the globe-Regulation vs. innovation.
    Wacker MG; Proykova A; Santos GML
    Int J Pharm; 2016 Jul; 509(1-2):95-106. PubMed ID: 27184102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory pathways for vaccines for developing countries.
    Milstien J; Belgharbi L
    Bull World Health Organ; 2004 Feb; 82(2):128-33. PubMed ID: 15042235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. United States Government Accountability Office report on nanotechnology: nanomaterials are widely used in commerce, but EPA faces challenges in regulating risk.
    United States Government Accountability Office
    Int J Occup Environ Health; 2010; 16(4):525-39. PubMed ID: 21222394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA holds public meeting on nanotechnology.
    Traynor K
    Am J Health Syst Pharm; 2006 Nov; 63(22):2175-7. PubMed ID: 17090732
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk management of nanomaterials.
    Gwinn MR; Tran L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(2):130-7. PubMed ID: 20077523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approaches to Develop Alternative Testing Strategies to Inform Human Health Risk Assessment of Nanomaterials.
    Stone V; Johnston HJ; Balharry D; Gernand JM; Gulumian M
    Risk Anal; 2016 Aug; 36(8):1538-50. PubMed ID: 27285586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.